Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHORTCUT
2024-513328-40-00Phase 4Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of trimethoprim + sulfamethoxazole in acute pyelonephritis, urinary tract infection (UTI) and bacterial disease (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary: Clinical cure at day 30 without additional antibiotics. Planned start Jun 2024; status: authorised.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
acute pyelonephritisurinary tract infection (UTI)bacterial disease
Beyond the preview
Go deeper on 2024-513328-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513328-40-00.